At ASHG 2025 held in Boston, I presented our latest research: leveraging complex disease genetics and evolution to dissect cross-ancestry genetics, selection, pleiotropy, aDNA introgression, and G*E🌹
Hope run a half marathon next time—the conference really cut running! 😄
These results highlight the ongoing disparities in both research output and global visibility within human genetics conferences.
🧵8/8
GDP and Nature Index Share, representing the economic and scientific capacity, respectively, were identified as key determinants of the average number of abstracts and oral presentations.
🧵7/8
Notably, China presented only 36 oral abstracts at ASHG and 13 at ESHG over the past 26 years. African and South American countries performed even less favorably, with fewer than 10 oral presentations each over the past two decades.
🧵6/8
Notably, Oceania had the highest talk acceptance rate.
Although East Asia ranked third overall, Japan (3.89% at ASHG; 5.93% at ESHG) and China (3.83% at ASHG; 12.26% at ESHG) had low visibility.
🧵5/8
North America and Europe consistently dominate. At ASHG, North America abstracts were ~4× more likely than East Asia’s and ~23× more likely than South America’s to be selected for oral presentations; at ESHG, Europe’s advantage was ~2× and ~9×.
🧵4/8
While disparities among research participants across ancestries have been well studied, the representation and disparities of researchers themselves on the global stage remains poorly understood.
🧵3/8
Equity in human genetics research requires balanced participation not only from study participants from global populations but also from the researchers who drive the science.
🧵2/8
We analyzed 100k+ abstracts (1999–2024) from ASHG & ESHG over the past two decades. www.medrxiv.org/content/10.1...
@medrxivpreprint.bsky.social @biorxiv-genetic.bsky.social @eshg.bsky.social @geneticssociety.bsky.social @ejhg-journal.bsky.social @geneticssociety.bsky.social
🧵1/8
At the European Society of Human Genetics (ESHG 2025) held in Milan, I presented our latest research progress: leveraging complex disease genetics and evolutionary genomics to investigate the genetic circuits of complex diseases and putative therapeutic targets. 🌹🌹🌹
